A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

Trial Details

NCT ID

NCT06067841

Phase

PHASE1

Sponsor

Bristol-Myers Squibb

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

• BMS-986460

Locations (sample)

• Palo Alto, California, United States|37.44188,-122.14302
• Sarasota, Florida, United States|27.33643,-82.53065
• Boston, Massachusetts, United States|42.35843,-71.05977
• New York, New York, United States|40.71427,-74.00597
• Durham, North Carolina, United States|35.99403,-78.89862

Key Eligibility Criteria

• Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.
• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.
• Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening
• Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-re…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.